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Abstract
Background: In non-small cell lung cancer (NSCLC) patients, concomitant idiopathic pulmonary fibrosis (IPF) and
emphysema (CPFE) are independently related to poor survival. CPFE is a condition with features of both pulmonary
fibrosis and emphysema. Here, we evaluated the effect of CPFE and IPF alone on the outcomes of NSCLC patients.
Patients and methods: We retrospectively evaluated 283 patients with CPFE or IPF who were diagnosed with
NSCLC between November 2003 and February 2018 at two tertiary care hospitals in South Korea. Patients were
classified into CPFE and IPF groups according to chest computed tomography findings.
Results: One-hundred-and-seven patients (37.8%; mean age: 70.1 years; men 97.2%) had CPFE. Compared with IPF
patients, CPFE patients had a heavier smoking history; lower diffusing capacity of carbon monoxide (78.0% vs
64.8%, p < 0.001), and lower forced expiratory volume in 1 s. Of all patients with NSCLC, 71.7% overall died during
the follow-up period; 71.6% died in the CPFE group and 72.0% in the IPF group. Multivariate logistic regression
analysis showed that CPFE (odds ratio [OR]: 2.26, 95% confidence interval [CI]: 1.09–4.69; P = 0.029) was significantly
correlated with acute exacerbations (AEs). In a Cox proportional hazards analysis, stage > III NSCLC, higher Eastern
Cooperative Oncology Group performance status, and higher gender–age–physiology index score was related to
higher mortality. However, CPFE was not related to a higher mortality rate in univariate (hazard ratio [HR]: 1.00; 95%
CI: 0.75–1.32, P = 0.972) or multivariate analysis (HR: 0.89; 95% CI: 0.66–1.21, P = 0.466).
Conclusions: AE risk, but not all-cause mortality, was higher in patients with CPFE and NSCLC than in those with IPF
and NSCLC. Physicians should be aware of the exaggerated risk of AE in patients with concomitant CPFE and NSCLC.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive fibrosing interstitial pneumonia, characterized by
progressively worsening dyspnea and lung function, and
is associated with a poor prognosis [1]. IPF is reportedly
associated with an increased risk of lung cancer [2]. Fur-
thermore, in non-small cell lung cancer (NSCLC) pa-
tients, concomitant IPF is related to poor survival [2, 3].
Emphysema is defined as an enlargement of the air
spaces distal to the terminal bronchioles due to destruc-
tion of the tissues comprising their walls, and can result
in an obstructive pattern. Emphysema is also associated
with an increased risk of lung cancer [4]. Furthermore,
the presence of emphysema in NSCLC patients is also
related to a poor prognosis [5].
Emphysema and IPF, which have different radiological,
pathological, functional, and prognostic characteristics,
have long been regarded as separate entities. However,
the coexistence of emphysema and pulmonary fibrosis in
individuals is being increasingly recognized [6]. In 2005,
Cottin et al. first proposed defining a syndrome termed
“combined pulmonary fibrosis and emphysema (CPFE),”
which is characterized by a heavy smoking history, exer-
cise hypoxemia, upper lobe emphysema and lower lobe
fibrosis, unexpectedly subnormal lung volumes, and se-
vere reduction of carbon monoxide transfer [7]. The
pathogenesis of CPFE has not yet been fully elucidated.
However, emphysema, IPF, and CPFE have common risk
factors, such as smoking [6]. The survival rates of pa-
tients with CPFE are known to be poor [8, 9]. Several
studies [6, 10–17] have evaluated the clinical course and
complications of CPFE. Among them, some reports have
stated that patients with CPFE have a higher risk of lung
cancer development and death compared with emphy-
sema patients [11, 16]. Nevertheless, the exact clinical
course and complications of CPFE are unclear, especially
when the condition is comorbid with lung cancer.
As the clinical course and complications of CPFE are not
fully understood, physicians may be more reluctant to treat
CPFE patients with concomitant NSCLC (CPFE-NSCLC)
[17]. Therefore, we aimed to evaluate whether (1) CPFE-
NSCLC patients are at higher odds of developing acute ex-
acerbations (AEs) than are IPF patients with NSCLC (IPF-
NSCLC) and whether (2) CPFE-NSCLC patients are at
higher risk of mortality than are IPF-NSCLC patients.
Methods
Study design and population
The study was conducted retrospectively in two tertiary
hospitals in South Korea. We evaluated all chest com-
puted tomography (CT) scans of patients with a diagnosis
of IPF and lung cancer that were obtained in the Sever-
ance Hospital and Seoul National University Bundang
Hospital between November 2003 and February 2018.
The inclusion criteria were as follows: (1) fulfilment of
diagnostic criteria of IPF and CPFE, (2) availability of CT
scan images at the time of diagnosis in the institutional
radiology database; and (3) availability of clinical data from
medical records. In total, 435 patients were considered
after applying the inclusion criteria. Among these, patients
were excluded if they (1) were diagnosed with small cell
lung cancer (n = 59); (2) had non-confirmed pathology
(n = 17); (3) had incomplete data available (n = 76); or (4)
were lost to follow-up (n = 20). Finally, 283 patients were
included in the analysis.
Clinical and laboratory data were collected retrospectively
from medical records. Data on age, smoking history, pul-
monary function test results, underlying diseases, height
and weight at the time of the diagnosis, gender–age–physi-
ology (GAP) index score [18], Eastern Cooperative Oncol-
ogy Group performance status (ECOG) [19], histological
type of NSCLC, and clinical and/or pathologic staging of
NSCLC were collected for all patients. Information on the
treatment modality used for NSCLC; date of treatment; AE
after surgery, chemotherapy, or radiotherapy (including the
date AE was confirmed); and mortality data (including
mortality due to AE) was also collected for all patients. Ac-
cording to smoking status, patients were categorized into
two groups (never-smoker vs. ever-smoker [a person who
had smoked at least 100 cigarettes and cigars during the
course of their life]). The GAP score was calculated based
on gender (0–1 points), age (0–2 points), forced vital cap-
acity (FVC) (0–2 points), and diffusing capacity of carbon
monoxide (DLco) (0–3 points), and was classified into
stages I (0–3 points), II (4–5 points), or III (6–8 points), as
previously described [18]. Early NSCLC was defined as
stage I or II, while advanced NSCLC was defined as stage
III or IV according to the eighth edition lung cancer stage
classification [20]. The primary outcome was the develop-
ment of AE and overall survival. Overall survival was esti-
mated from the date of diagnosis of NSCLC and IPF/CPFE
until death. Death registration data were provided by the
Ministry of Security and Public Administration of Korea.
Diagnostic criteria for IPF, CPFE, and AE
IPF was diagnosed using the criteria for the usual intersti-
tial pneumonia (UIP) pattern as described in an official
ATS/ERS/JRS/ALAT statement [21], as follows: sub-
pleural, basal, predominantly reticular abnormality or
honeycombing, with or without traction bronchiectasis,
and the absence of an inconsistent UIP pattern. Diagnosis
was confirmed at each hospital by a multi-disciplinary
team consisting of specialists in pulmonary medicine, radi-
ology, and pathology.
CPFE was defined according to Cottin et al.’s and Ryer-
son et al.’s definitions, namely the presence of classic fea-
tures of centrilobular and/or paraseptal emphysemas (≥
10%) in the upper lobes and pulmonary fibrosis (mainly
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IPF/UIP) in the lower lobes radiographically [7, 13]. Clas-
sification of CPFE and IPF was based on radiologic find-
ings on chest CT scans. All CT scans of the included
patients were reviewed by two radiologist and four pulmo-
nologists, independently.
AE was defined according to the International Working
Group Report by Collard et al. [22]: previous or concurrent
diagnosis of IPF, acute worsening or development of dys-
pnea, typically < 1month in duration, and CT scan with
new bilateral ground-glass opacity and/or consolidation,
with the deterioration not fully explained by cardiac failure
or fluid overload. In the present study, acute exacerbation of
IPF or CPFE within 1month after treatment (chemotherapy,
surgery, or radiotherapy) was defined as AE, in order to
evaluate the effect of CPFE on the treatment of NSCLC.
Statistical analysis
Baseline characteristics of CPFE-NSCLC and IPF-
NSCLC patients were compared using an unpaired t-test
for continuous variables or χ2 test for categorical vari-
ables and are presented as mean ± standard deviation
and numbers (percentage). Multiple logistic regression
models were used to estimate odds ratios (ORs) for AE.
Survival times were estimated using the Kaplan–Meier
method and compared with the log-rank test. Multivari-
ate Cox proportional hazards models were performed to
investigate the relationships between clinical parameters
and mortality. Variables that overlapped (e.g., age, gen-
der, FVC, and DLCO in the GAP index) were excluded in
the multivariate Cox proportional hazards models. An
adjusted P-value < 0.05 was considered statistically sig-
nificant. All statistical analyses were performed with
SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).
Ethics statement
This research protocol was approved by the Institutional
Review Board of Severance Hospital, South Korea (IRB
No. 4–2018-0770). The study design was approved by
the appropriate ethics review boards. The requirement
to obtain informed patient consent was waived.
Results
Baseline characteristics
Baseline characteristics of the study subjects are pro-
vided in Table 1. Men constituted 95.1% of the study co-
hort. The mean age for the patients overall was 70.3
years (range, 46–89 years); the mean ages of CPFE and
IPF patients were 70.4 years (range, 46–89 years) and
70.1 years (range, 51–87 years), respectively. Compared
with IPF patients, CPFE patients had a heavier smoking
history, lower DLco (78.0% vs. 64.8%, P < 0.001), and
lower forced expiratory volume in 1 s (FEV1)/FVC ratio
(75.1% vs. 71.2%, P = 0.001). Body mass index (BMI),
FVC, NSCLC histology, FVC predicted %, FEV1
predicted %, NSCLC stage, ECOG status, treatment mo-
dality, and GAP score did not differ significantly be-
tween IPF and CPFE patients.
Of the NSCLC patients overall, 71.7% died during the
follow-up period; 71.6% died in the CPFE group and
72.0% in the IPF group. The respective follow-up periods
were 18.6 months and 24.1 months (P = 0.975). CPFE pa-
tients had an increased tendency to develop AE, al-
though this was not statistically significant in the
univariate analysis (12.5% vs. 21.3%, P = 0.098). The time
elapsed between diagnosis of CPFE or IPF and NSCLC
was analyzed but did not differ significantly between the
two groups (16.1 months vs. 16.4 months, P = 0.937).
AE and CPFE
Additional file 1: Table S1 shows the incidences of AE
after treatment according to the treatment modality.
Nine patients had undergone surgery and adjuvant
chemotherapy, 22 patients had undergone concurrent
chemoradiation therapy, and four patients had under-
gone surgery, followed by concurrent chemoradiation
therapy. All AE were calculated separately after the re-
spective treatments. NSCLC patients with CPFE tended
to have more AE after surgery (IPF 8.6% vs. CPFE 21.6%,
P = 0.073). Although the incidence of AE was higher in
the CPFE group (13.1% vs. 21.3%, P = 0.098), no statisti-
cally significant difference was found.
Table 2 shows the relationship between CPFE and AE
in the logistic regression model. GAP stage, smoking sta-
tus, NSCLC histology, NSCLC stage, and CPFE were in-
cluded in the regression model. In the analysis, due to
the small number of patients in the GAP stage III group
(n = 14), this group was combined with the GAP stage II
group. CPFE (OR: 2.26, 95% CI: 1.09–4.69, P = 0.029)
and GAP stage > II (OR: 2.20; 95% CI: 1.05–4.64; P =
0.037) showed a significant correlation with AE. NSCLC
histology, smoking history (ever-smoker), and NSCLC
stage > III did not show significant correlations with AE.
Survival and CPFE
There was no significant difference in survival rates be-
tween the IPF and CPFE groups (P = 0.972), according to
analysis of the Kaplan–Meier survival curves (Fig. 1).
The relationships between all-cause mortality and clinical
parameters, including CPFE, were evaluated using Cox pro-
portional hazards analysis (Table 3). Univariate analysis
showed that advanced stage NSCLC, higher GAP index
score (P < 0.001), AE (P < 0.001), lower FVC predicted,
lower FEV1 predicted, lower DLco predicted, higher FEV1/
FVC, %, and histological type other than adenocarcinoma or
squamous cell carcinoma were significantly correlated with
all-cause mortality. BMI, smoking history, time elapsed be-
tween diagnosis of IPF or CPFE and diagnosis of NSCLC,
and CPFE did not correlate with all-cause mortality.
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Multivariate Cox proportional hazards analyses were
performed to compare the contributions of these indi-
ces (Table 4). Stepwise Cox proportional hazards ana-
lysis demonstrated that higher ECOG status (HR:
1.30; 95% CI: 1.16–1.55; P = 0.003), advanced stage
NSCLC (HR: 3.15; 95% CI: 2.21–4.49; P < 0.001), and
higher GAP score (HR: 1.31; 95% CI: 1.16–1.48;
P < 0.001) were risk factors for all-cause mortality.
CPFE (HR: 0.89; 95% CI: 0.66–1.21; P = 0.466) was
not a significant risk factor for all-cause mortality in
multivariate analysis.
Discussion
In this study, we have described differences in clinical fea-
tures and outcomes between NSCLC-IPF and NSCLC-
CPFE. Although previous studies have compared CPFE to
IPF, few studies have compared CPFE-NSCLC to IPF-
NSCLC. We demonstrated that CPFE is related to AE, but
is not a significantly greater risk factor of all-cause mortal-
ity compared with IPF in NSCLC patients.
In this study, the prevalence of CPFE was 37.8% in pa-
tients with NSCLC and pulmonary fibrosis. In previously
reported studies, the proportion of patients with CPFE
Table 1 Patient characteristics according to the presence of CPFE
Variable IPF-NSCLC CPFE-NSCLC P-value
Number of patients, n (%) 176 (62.2%) 107 (37.8%)
Age, years 70.4 ± 8.4 (46–89) 70.1 ± 7.1 (51–87) 0.810
Sex, men 165 (93.8%) 104 (97.2%) 0.263
BMI, kg/m2 23.4 ± 3.2 (15.2–30.7) 22.9 ± 3.2 (13.3–29.8) 0.222
Ever smoker, % 161 (91.5%) 103 (96.3%) 0.145
Smoking history,
pack-years
35.6 ± 23.8 (0–120) 46.4 ± 26.4 (0–180) < 0.001
Histology, numbers (%) 0.344
Adenocarcinoma 67 (38.1%) 50 (46.7%)
Squamous cell carcinoma 84 (47.7%) 45 (42.1%)
Others 25 (14.2%) 12 (11.2%)
FVC, % predicted 83.3 ± 18.8 (34–125) 82.8 ± 17.4 (41–121) 0.844
FEV1, % predicted 90.2 ± 20.7 (5–140) 86.0 ± 18.7 (44–135) 0.091
DLCO, % predicted (n = 249) 78.0 ± 21.5 (33–128) 64.8 ± 17.9 (16–102) < 0.001
FEV1/FVC, Percentage 75.1 ± 8.4 (48.2–96.3) 71.2 ± 9.6 (16–102) 0.001
NSCLC Stage, numbers (%) 0.617
Stage I 45 (25.6%) 27 (25.2%)
Stage II 27 (15.3%) 13 (12.1%)
Stage III 38 (21.6%) 30 (28.0%)
Stage IV 66 (37.5%) 37 (34.6%)
ECOG ≥2, n (%) 38 (21.6%) 16 (15.0%) 0.106
Follow-up time, months 24.1 ± 24.1 (0.0–138.0) 18.6 ± 25.5 (0.3–137.8) 0.975
Time Gap between Diagnosis
of IPF or CPFE and Diagnosis
of NSCLC, months
16.4 ± 30.7 (0–149.6) 16.1 ± 31.1 (0–148.4) 0.937
GAP Index score 3.17 ± 1.19 (1–8) 3.38 ± 1.21 (1–7) 0.166
Received chemotherapy,
n (%)
78 (44.3%) 53 (49.5%) 0.461
Received operation,
n (%)
73 (41.7%) 37 (34.9%) 0.313
Received radiotherapy,
n (%)
24 (13.6%) 20 (18.7%) 0.310
AE, n (%)a 19 (12.5%) 19 (21.3%) 0.098
Continuous variables are presented as mean ± SD (range) and categorical variables are presented as numbers (percentage)
Definition of abbreviations: BMI, Body Mass Index; CPFE, Combined Pulmonary Fibrosis and Emphysema; NSCLC, Non-Small Cell Lung Cancer; ECOG, Eastern
Cooperative Oncology Group performance status; AE, Acute Exacerbation; GAP Score, Gender–Age–Physiology Score; FVC, Forced Vital Capacity; FEV1, forced
expiratory volume in 1 s; DLCO, diffusing capacity of carbon monoxide
aAE data could be collected from 241/283 patients
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detectable on a high-resolution CT scan ranged from 8
to 51% in IPF patients [13, 23]. As the prevalence of lung
cancer in CPFE is reported to be higher than that in IPF
patients (50% vs. 14.5%) [24], the prevalence reported in
this study is in accordance with the findings of previous
studies. Cigarette smoking is the main risk factor for
NSCLC, IPF, and emphysema, and IPF and emphysema
are additional independent risk factors for NSCLC; thus,
it is plausible that CPFE patients have a heavier smoking
history and higher prevalence of NSCLC. The average
smoking pack-years were higher in the CPFE group than
in the IPF group in our study. These conditions also
share many pathogenic pathways, including genetic and
epigenetic alterations, tissue invasion, uncontrolled
proliferation, and activation of specific signal transduc-
tion pathways [25].
We assessed the median duration from the diagnosis
of CPFE/IPF and diagnosis of NSCLC in patients who
developed CPFE/IPF prior to developing NSCLC. The
duration did not differ between the CPFE and IPF
groups (20.01 months vs. 21.06 months, P = 0.618). This
may suggest that CPFE patients do not necessarily need
a shorter follow-up period compared with IPF patients
to monitor for the presence of lung cancer. The result
did not differ when the patients who were diagnosed
concurrently (i.e., diagnosed with NSCLC within 1
month before or after the diagnosis of IPF or CPFE)
were excluded (43.0 months vs. 38.5 months, P = 0.670).
The annual incidence of AE in patients with IPF has been
reported as 5–15% [26]. Additionally, the incidence rate of
AE triggered by chemotherapy [27], surgery [28], and radio-
therapy [29] is increased in patients with IPF. In our study,
the total incidence of AE was 15.7%. We found that CPFE
was an independent risk factor of AE after treatment of
NSCLC, similar to advanced IPF (higher GAP stage). In a
retrospective study of 487 patients who underwent lobec-
tomy for lung cancer, Saito et al. found that seven of 10
post-lobectomy acute respiratory distress syndrome cases
(70%) had CPFE [30]. In Japan, Minegishi et al. have re-
ported that the incidence of AE associated with anticancer
treatment in lung cancer patients with interstitial lung dis-
ease is 10–30% for surgical resection and 9–21% for
chemotherapy [12]. In our study, surgical resection patients
with CPFE were at higher odds of developing AEs than
were patients with IPF. Our study adds evidence that,
Fig. 1 Kaplan–Meier survival curves stratified by the presence of combined pulmonary fibrosis and emphysema (CPFE)
Table 2 Logistic regression analyses of factors related to AE
Variable OR 95% CI p-value
GAP stage,
II and III
2.20 1.05–4.64 0.037
Ever smoker 3.05 0.38–24.23 0.292
Histology
Adenocarcinoma 1.00
Squamous cell
carcinoma
0.60 0.26–1.36 0.220
Others 1.04 0.35–3.11 0.950
NSCLC stage ≥ III 1.85 0.83–4.16 0.135
CPFE 2.26 1.09–4.69 0.029
Values are presented as odds ratios (ORs) with 95% confidence intervals (CIs)
Definition of abbreviation: GAP Score Gender–Age–Physiology Score, NSCLC
Non-Small Cell Lung Cancer, CPFE Combined Pulmonary Fibrosis
and Emphysema
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regardless of whether invasive or non-invasive treatment is
used, CPFE may increase the risk of AE.
In IPF and lung cancer patients, efforts are being made
to prevent the development of AE. Iwata et al. showed
that perioperative pirfenidone for lung cancer surgery in
patients with IPF significantly decreased the incidence of
AE after surgery [31]. This may also apply to CPFE pa-
tients, but further studies are required.
CPFE did not affect the mortality rate of NSCLC pa-
tients, although AE has been associated with increased
mortality. AEs of IPF are a well-described complication
after lung resection, with an incidence of approximately
15% and mortality of 33.3–100% in some studies [32]. It
is possible that, in IPF-NSCLC and CPFE-NSCLC pa-
tients, the main prognostic factor is the NSCLC stage.
Similarly, Goto et al. [33] showed that IPF is a prognos-
tic factor in stage I/II NSCLC, but not in stage III/IV
NSCLC. Another possibility is that the outcomes of AEs
of CPFE could be more favorable than those of IPF.
Toyoshima et al. [34] have reported that, in a compari-
son of AEs of CPFE and IPF, the AEs of CPFE had a
more favorable outcome. Lastly, it is possible that the
general prognosis of CPFE-NSCLC patients is better
than that of IPF-NSCLC patients, without AEs. Some
studies have indicated a much worse prognosis for CPFE
than for IPF [35, 36]. However, there are data indicating
that CPFE patients have the same [10] or even longer
survival [37] compared with IPF subjects. Further studies
are needed on this matter.
Our study had some limitations. First, it included only
Korean patients and only two centers participated in the
study. Some studies of drug-induced lung injury have
suggested ethnic differences in the susceptibility to acute
progressive respiratory failure during the course of IPF
Table 4 Clinical factors associated with all-cause mortality
(multivariate analysis)
Variables HR 95% CI P value
BMI, kg/m2 0.99 0.95–1.04 0.775
CPFE, yes 0.89 0.66–1.21 0.466
NSCLC Stage ≥ III 3.15 2.21–4.49 < 0.001
ECOG 1.30 1.09–1.55 0.003
GAP Score 1.31 1.16–1.48 < 0.001
Histologic type
Adenocarcinoma 1.00
Squamous cell carcinoma 0.97 0.70–1.34 0.849
Others 1.27 0.80–1.99 0.309
Data are presented as hazard ratios (95% confidence intervals)
Definition of abbreviations: BMI Body Mass Index, CPFE Combined Pulmonary
Fibrosis and Emphysema, NSCLC Non-Small Cell Lung Cancer, ECOG Eastern
Cooperative Oncology Group performance status, GAP Score
Gender–Age–Physiology Score
Table 3 Clinical factors associated with all-cause mortality (univariate analysis)
Variables HR 95% CI P value
BMI, kg/m2 0.92 0.88–0.96 < 0.001
Ever Smoker, Yes 0.897 0.55–1.46 0.897
CPFE, yes 0.995 0.75–1.32 0.972
NSCLC Stage ≥ III 3.68 2.69–5.03 < 0.001
ECOG 1.44 1.24–1.68 < 0.001
AE, Yes 2.91 1.73–4.91 < 0.001
GAP Score 1.50 1.33–1.70 < 0.001
Sex, Male 0.971 0.54–1.74 0.920
FVC, % Predicted 0.98 0.98–0.99 < 0.001
FEV1, % Predicted 0.97 0.96–0.98 < 0.001
DLco, % Predicted 0.98 0.98–0.99 < 0.001
FEV1/FVC, % 1.03 1.01–1.04 0.004
Time Gap between Diagnosis
of IPF or CPFE and Diagnosis
of NSCLC, months
1.00 1.00–1.01 0.265
Histologic type
Adenocarcinoma 1.00
Squamous cell carcinoma 0.93 0.69–1.26 0.647
Others 1.68 1.10–2.55 0.016
Data are presented as hazard ratios (95% confidence intervals)
Definition of abbreviations: BMI Body Mass Index, CPFE Combined Pulmonary Fibrosis and Emphysema, NSCLC Non-Small Cell Lung Cancer, ECOG Eastern
Cooperative Oncology Group performance status, AE Acute Exacerbation, GAP Score Gender–Age–Physiology Score, FVC Forced Vital Capacity, FEV1 forced
expiratory volume in 1 s, DLCO diffusing capacity of carbon monoxide
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[38]. Large multiregional prospective studies are needed
to eliminate an ethnic bias. Second, there might have
been bias in patient selection. Of the patients who met
the inclusion criteria, the proportion of patients who
had incomplete data or who were lost to follow-up was
high (22%). Furthermore, as our study population com-
prised patients who underwent chest CT scans at a ter-
tiary hospital, the population may not be fully
representative of the disease population.
Conclusions
In conclusion, the risk of AE was higher in patients with
CPFE and NSCLC, but all-cause mortality was not
higher in NSCLC patients with concomitant CPFE than
in those with concomitant IPF. Physicians should be
aware of the increased risk of AE when treating NSCLC
patients with CPFE. A multidisciplinary approach is re-
quired for treating these patients.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12890-019-0951-2.
Additional file 1: Table S1. Incidence of acute exacerbation according
to treatment modality.
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